# An Open Label Study To Evaluate The Safety and Kinetics of Nelfinavir in Subjects With HIV and Hepatitis C

> **NCT00141284** · PHASE4 · COMPLETED · sponsor: **Pfizer** · enrollment: 12 (actual)

## Conditions studied

- HIV Infection
- Hepatitis C

## Interventions

- **DRUG:** nelfinavir 1,250 mg twice daily
- **DRUG:** Zidovudine 300 mg twice daily
- **DRUG:** Lamivudine 150 mg twice daily

## Key facts

- **NCT ID:** NCT00141284
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2006-12
- **Final completion:** 2006-12
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2011-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00141284

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00141284, "An Open Label Study To Evaluate The Safety and Kinetics of Nelfinavir in Subjects With HIV and Hepatitis C". Retrieved via MORVS 2026-10-24 from https://api.morvs.ai/clinical/NCT00141284. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*